Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13681654 | 0.95 | AHR (0.42) | SMN1; SMN2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL13681661 | 0.82 | DRD2 (0.42) | SMN1; SMN2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL25369942 | 0.79 | LTA4H (0.50) | LMNA | |
| SCHEMBL5854524 | 0.77 | PLA2G4B (0.57) | ALDH1A1HTTPOLBTDP1 | |
| SCHEMBL1629693 | 0.77 | HRH3 (0.43) | SMN1; SMN2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL20204806 | 0.76 | MAPT (0.47) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL578484 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1TDP1 | |
| SCHEMBL20568979 | 0.76 | APP (0.41) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17589883 | 0.76 | PPARA (0.60) | KDM4EALDH1A1LMNAGAAPPARA | |
| SCHEMBL17589885 | 0.76 | PPARA (0.44) | HTTPOLBTDP1GAAPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116685-A1 | Method for solution phase synthesis of oligonucleotides | PROLIGO LLC | 2004-06-17 | — | — | US | disclosed |
| US-6262251-B1 | PRODUCT ANCHORED SEQUENCIAL SYNTHESIS (PASS); AN ANCHOR GROUP ATTACHED TO THE 5' END OF THE GROWING OLIGONUCLEOTIDE PRODUCT ALLOWS THE COUPLED PRODUCT TO BE SEPARATED FROM UNREACTED STARTING MATERIALS | PROLIGO LLC | 2001-07-17 | — | — | US | disclosed |
| EP-0979233-A4 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | PROLIGO L L C (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-0979233-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | NeXstar Pharmaceuticals, Inc. (US) | 2000-02-16 | — | — | EP | disclosed |
| US-6001966-A | REACTING N-TERMINAL PROTECTED AMINO ACID WITH PEPTIDE STARTING MATERIAL FORMING A PEPTIDE PRODUCT, PARTITIONING FROM UNREACTED MATERIAL AND REAGENTS BASED ON PRESENCE OF N-TERMINAL BLOCKING/ANCHORING GROUP | PROLIGO LLC (US) | 1999-12-14 | — | — | US | disclosed |
| US-5874532-A | USING A N-TERMINAL PROTECTED AMINO ACID MONOMER | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1998047910-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | PROLIGO LLC (US) | 1998-10-29 | — | — | WO | disclosed |